Thermo Fisher Q3 revenue up 9.1% to $12.1B; net income $1.72B, buyback authorization cut to $1B

Filed October 30, 2026 · Period ending September 26, 2026 · Compared to 10-Q Oct 31, 2025 · ~1 min read

Key Changes

• high

  Revenue rose 9.1% to $12.1B, with operating income up 17% to $2.3B, driven by strong pharma/biotech demand and the Clario acquisition.

  MD&A verify on EDGAR →
• high

  Net income increased 6.5% to $1.72B, and diluted EPS rose 8.7% to $4.64.

  Key Financials view on EDGAR →
• high

  Share repurchases totaled $4.0B in the first nine months, reducing the buyback authorization to $1.0B remaining.

  MD&A verify on EDGAR →